Recent News and Updates
Orphalan Partners with MAP International and the Wilson Disease Association to Provide Life-Changing Medicine to Underserved Communities
Orphalan SA, a global pharmaceutical company focused on rare diseases, is partnering with MAP International and the Wilson Disease Association (WDA) to provide Cuvrior® (trientine tetrahydrochloride) to patients with Wilson Disease in developing countries. Through [...]
Important change for Wilson disease patients taking Galzin
WD Patients taking prescription zinc can now get their Galzin from a specialty pharmacy […]
WDA designates Wilson Disease Center of Excellence at University of Miami
Read more: Press Release
Ultragenyx letter to the WD community
Read more: WDA Community Update from Ultragenyx Oct 2024 (PDF)
Gene therapy updates from the WDA
Read more: GTx-Updates (PDF)


